There are no approved vaccines for HSV, and GSK’s decision to stop developing ... an investigational vaccine for herpes ...
GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.
buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Hosted on MSN2mon
It’s rarely lethal, but genital herpes costs the world $35 billion a year and 20% of people have itSymptomatic HSV-2 infection is also associated with an ... and therapeutics that reduce severity and viral load. Another company, GSK, completed a vaccine trial in September 2024, but the vaccine ...
GSK blames political and regulatory pressures ... with Zhifei now set to purchase 21.6bn yuan ($2.97bn) worth of the vaccine over six years. The revision follows a sharp downturn in China ...
Two earlier trials demonstrated that a vaccine based on the HSV-2 glycoprotein D subunit (gD-2) was effective in protecting HSV-1/HSV-2-seronegative women whose sexual partners had recurrent HSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback